Macrocyclic Chalcone-Amide Inhibitors for PLpro
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for coronavirus infections, such as those targeting the 3CLpro and RdRp, face challenges with drug resistance and the need for more effective oral antiviral agents that can address the coronavirus lifecycle and restore host antiviral immunity.
Innovation Solution
Development of novel antiviral compounds that inhibit the coronavirus Papain-Like protease (PLpro), represented by specific chemical structures, to interfere with the viral lifecycle and enhance host immunity, potentially used in combination with other therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies targeting 3CLpro and RdRp are used, then viral replication is inhibited, but drug resistance develops and antiviral immunity is not restored
Solution Approach 1:
The invention segments the antiviral strategy by introducing a new molecular target (PLpro) distinct from existing 3CLpro and RdRp inhibitors. This segmentation creates a separate therapeutic pathway that does not cross-resist with current drugs, thereby addressing the drug resistance problem while maintaining antiviral effectiveness.
Solution Approach 2:
The PLpro inhibitor is designed to perform multiple functions: directly inhibiting viral replication through PLpro blockade and simultaneously restoring host antiviral immunity by preventing immune evasion. This multi-functionality enhances therapeutic effectiveness while providing a novel mechanism that bypasses existing drug resistance.
2Reliability
If PLpro activity is inhibited, then viral replication is suppressed and antiviral immunity is restored, but new therapeutic agents are required
Solution Approach 1:
The invention provides detailed synthetic routes and preparation methods for PLpro inhibitors in advance, enabling pharmaceutical manufacturers to produce these novel therapeutic agents. The preliminary disclosure of synthesis protocols facilitates timely drug availability once clinical need is established.
3Adaptability or versatility
If novel PLpro inhibitors are developed, then drug resistance is reduced and immunity is restored, but therapeutic complexity increases
Solution Approach 1:
The invention merges two therapeutic benefits into a single agent: viral replication inhibition and immune restoration. By combining these functions in one PLpro inhibitor molecule, the treatment regimen remains relatively simple while achieving multiple therapeutic goals that reduce drug resistance.
Data Source
AI summary
The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.